| HLA-DRB9 |
|
major histocompatibility complex, class II, DR beta 9 (pseudogene)
|
|
|
0.682 |
0.654 |
| HCG9 |
|
HLA complex group 9
|
|
|
0.700 |
0.500 |
| SNHG32 |
|
small nucleolar RNA host gene 32
|
|
2.4E-02 |
0.805 |
0.308 |
| HLA-S |
|
major histocompatibility complex, class I, S (pseudogene)
|
|
|
0.931 |
0.192 |
| COL11A2P1 |
|
collagen type XI alpha 2 pseudogene 1
|
|
|
0.805 |
0.462 |
| LINC02649 |
|
long intergenic non-protein coding RNA 2649
|
|
|
0.792 |
0.308 |
| LINC00243 |
|
long intergenic non-protein coding RNA 243
|
|
|
0.729 |
0.423 |
| TRIM26BP |
|
tripartite motif containing 26B, pseudogene
|
|
|
0.861 |
0.269 |
| HCG18 |
|
HLA complex group 18
|
|
|
0.722 |
0.538 |
| HCG17 |
|
HLA complex group 17
|
|
|
0.769 |
0.346 |
| HLA-DPA2 |
|
major histocompatibility complex, class II, DP alpha 2 (pseudogene)
|
|
|
0.780 |
0.538 |
| PSMB8-AS1 |
|
PSMB8 antisense RNA 1 (head to head)
|
|
|
0.839 |
0.385 |
| MSH5-SAPCD1 |
|
MSH5-SAPCD1 readthrough (NMD candidate)
|
|
|
0.760 |
0.423 |
| ATP6V1G2-DDX39B |
|
ATP6V1G2-DDX39B readthrough (NMD candidate)
|
|
|
0.769 |
0.423 |
| PPT2-EGFL8 |
|
PPT2-EGFL8 readthrough (NMD candidate)
|
|
|
0.792 |
0.462 |
| TSBP1-AS1 |
|
TSBP1 and BTNL2 antisense RNA 1
|
|
|
0.638 |
0.692 |
| LINC02357 |
|
long intergenic non-protein coding RNA 2357
|
|
|
0.805 |
0.231 |
| LINC02571 |
|
long intergenic non-protein coding RNA 2571
|
|
|
0.743 |
0.500 |
| EHMT2-AS1 |
|
EHMT2 and SLC44A4 antisense RNA 1
|
|
|
0.780 |
0.462 |
| LST1 |
O00453
|
leukocyte specific transcript 1
|
|
1.1E-03 |
0.792 |
0.308 |
| MSH5 |
O43196
|
mutS homolog 5
|
Nucleic acid binding
|
3.2E-11 |
0.641 |
0.692 |
| APOM |
O95445
|
apolipoprotein M
|
|
9.6E-04 |
0.590 |
0.769 |
| MPIG6B |
O95866
|
megakaryocyte and platelet inhibitory receptor G6b
|
|
1.1E-06 |
0.695 |
0.500 |
| LY6G6C |
O95867
|
lymphocyte antigen 6 family member G6C
|
|
4.9E-04 |
0.821 |
0.385 |
| LY6G6D |
O95868
|
lymphocyte antigen 6 family member G6D
|
|
3.3E-02 |
0.805 |
0.385 |